Rheumatoid Arthritis

Latest News


CME Content


Talk Health, Not Weight

By

Although the stakes couldn’t be higher and the promotion of healthy behavior is paramount, the emphasis on BMI and weight is likely to yield little benefit. The Association for Size Diversity and Health (ASDAH) developed Health at Every Size (HAES) to take the focus off of weight change and place it more squarely on health, thus supporting people of all sizes to take care of themselves and improve health outcomes.

In rheumatoid arthritis, physician scientists are beginning to zero in on personalized medicine. In this interview, Dr. Leslie R. Harrold, chief scientific officer of Corrona, and a University of Massachusetts associate professor, summarizes a study she recently presented at ACR 2020 in which she describes biomarkers and patient characteristics she and her team have identified as taking us one step closer to precision medicine.

Direct Costs to Patients for RA Treatment:  $12,509-$36,053

The annual direct costs for rheumatoid arthritis (RA) patients are estimated to range from $12,509-$36,053. A late diagnosis costs even more and one in 10 new RA cases are usually diagnosed late. In this presentation, Kathryn Johnson, RPh, of CVS Health breaks down the numbers.

ACR Set to Issue Updated RA Treatment Guidelines

The American College of Rheumatology is expected to issue updated treatment guidelines for rheumatoid arthritis no later than spring 2021. The new guidelines will include recommended uses for biologics approved since the last update in 2015―including JAK inhibitors.

ACR Conference Roundup:  New RA Treatment Guidelines Preview

In this week's news roundup from Rheumatology Network, we highlight studies presented at the annual meeting of the American College of Rheumatology, which wrapped this week. Among the stories we covered included a preview of the soon-to-be released rheumatoid arthritis guidelines, promising new treatments for lupus nephritis and advances in osteoporosis care. Learn more in today's news roundup.

Q&A: Methotrexate and Tuberculosis

Tuberculosis screening and ongoing clinical care is needed for patients prescribed methotrexate, particularly if co-administered with corticosteroids or other immunosuppressants, who live in areas where tuberculosis is common, according to researchers recently reporting at the annual meeting of the American College of Rheumatology.

Tofacitinib, Adalimumab, Methotrexate Show Similar Influenza Adverse Events in RA

In a study that examined the influenza adverse events (AEs) of tofacitinib (Xeljanz, Pfizer) in patients with rheumatoid arthritis, similar AEs were seen with tofacitinib, adalimumab, methotrexate, and placebo, and between different tofacitinib doses and patient age groups, according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.

In a study presented at the annual meeting of the American College of Rheumatology, UK researchers showcase a study in which artificial intelligence was successfully used to identify ACPA positivity and CRP of greater than 12.3 mg/L to identify rheumatoid arthritis patients more likely to respond to sarilumab.

minorities rheumatic disease acr annual meeting

In a study that explored the longitudinal racial disparities in rheumatoid arthritis treatment and emergency department use, black rheumatoid arthritis patients were found to be less likely to receive biologics and instead, be given a prescription for glucocorticoids, say researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

Rheumatic Disease Research Driven by Smartwatch Data

Rheumatoid arthritis patients overwhelmingly embraced the idea of collecting patient reported outcomes by smartwatch, shows a study due to be presented on Monday in a presentation to be given at the American College of Rheumatology annual meeting.